Business Description
Novo Nordisk A/S
NAICS : 325412
SIC : 2836
ISIN : US6701002056
Compare
Compare
Traded in other countries / regions
NVO.USANOVO B.Denmark0QIU.UKNOV.GermanyN1VO34.BrazilNOVOB.MexicoNNO2.AustriaNOVOB.Switzerland IPO Date
1981-07-09Description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.42 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | 0.29 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 11.19 | |||||
| Beneish M-Score | -2.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.9 | |||||
| 3-Year EBITDA Growth Rate | 13.9 | |||||
| 3-Year EPS without NRI Growth Rate | 14.3 | |||||
| 3-Year FCF Growth Rate | 23.6 | |||||
| 3-Year Book Growth Rate | 15.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 5.94 | |||||
| Future 3-5Y Total Revenue Growth Rate | 20.14 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.22 | |||||
| 9-Day RSI | 39.82 | |||||
| 14-Day RSI | 46.09 | |||||
| 6-1 Month Momentum % | 20.51 | |||||
| 12-1 Month Momentum % | 94.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.88 | |||||
| Quick Ratio | 0.7 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 284.93 | |||||
| Days Sales Outstanding | 90.19 | |||||
| Days Payable | 153.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.12 | |||||
| Dividend Payout Ratio | 0.41 | |||||
| 3-Year Dividend Growth Rate | 11 | |||||
| Forward Dividend Yield % | 1.12 | |||||
| 5-Year Yield-on-Cost % | 1.6 | |||||
| 3-Year Average Share Buyback Ratio | 2.1 | |||||
| Shareholder Yield % | 2.44 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.35 | |||||
| Operating Margin % | 42.8 | |||||
| Net Margin % | 33.4 | |||||
| ROE % | 83.02 | |||||
| ROA % | 27.25 | |||||
| ROIC % | 28.95 | |||||
| ROC (Joel Greenblatt) % | 120.08 | |||||
| ROCE % | 68.82 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 43.76 | |||||
| Forward PE Ratio | 31.77 | |||||
| PE Ratio without NRI | 43.76 | |||||
| Shiller PE Ratio | 68.91 | |||||
| Price-to-Owner-Earnings | 55.6 | |||||
| PEG Ratio | 4.33 | |||||
| PS Ratio | 14.79 | |||||
| PB Ratio | 32.4 | |||||
| Price-to-Tangible-Book | 73.87 | |||||
| Price-to-Free-Cash-Flow | 44.2 | |||||
| Price-to-Operating-Cash-Flow | 33.23 | |||||
| EV-to-EBIT | 35.94 | |||||
| EV-to-Forward-EBIT | 25.12 | |||||
| EV-to-EBITDA | 32.7 | |||||
| EV-to-Forward-EBITDA | 23.06 | |||||
| EV-to-Revenue | 14.34 | |||||
| EV-to-Forward-Revenue | 11.1 | |||||
| EV-to-FCF | 42.92 | |||||
| Price-to-Projected-FCF | 4.02 | |||||
| Price-to-DCF (Earnings Based) | 2.63 | |||||
| Price-to-DCF (FCF Based) | 2.53 | |||||
| Price-to-Median-PS-Value | 1.83 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.39 | |||||
| Price-to-Graham-Number | 12.01 | |||||
| Earnings Yield (Greenblatt) % | 2.78 | |||||
| Forward Rate of Return (Yacktman) % | 14.55 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:NVO
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novo Nordisk A/S Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 28,487.63 | ||
| EPS (TTM) ($) | 2.11 | ||
| Beta | 0.59 | ||
| Volatility % | 25.17 | ||
| 14-Day RSI | 46.09 | ||
| 14-Day ATR ($) | 2.059577 | ||
| 20-Day SMA ($) | 94.6225 | ||
| 12-1 Month Momentum % | 94.4 | ||
| 52-Week Range ($) | 48.585 - 100.88 | ||
| Shares Outstanding (Mil) | 4,472.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novo Nordisk A/S Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novo Nordisk A/S Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novo Nordisk A/S Frequently Asked Questions
What is Novo Nordisk A/S(NVO)'s stock price today?
The current price of NVO is $92.34. The 52 week high of NVO is $100.88 and 52 week low is $48.59.
When is next earnings date of Novo Nordisk A/S(NVO)?
The next earnings date of Novo Nordisk A/S(NVO) is 2023-11-02.
Does Novo Nordisk A/S(NVO) pay dividends? If so, how much?
The Dividend Yield %  of Novo Nordisk A/S(NVO) is 1.12% (As of Today), Highest Dividend Payout Ratio of Novo Nordisk A/S(NVO) was 0.63. The lowest was 0.37. And the median was 0.47. The  Forward Dividend Yield % of Novo Nordisk A/S(NVO) is 1.12%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers